Celsion rises on positive ThermoDox data


Celsion (CLSN) shares +4.2% after saying that the latest data from a Phase III study of its ThermoDox treatment for hepatocellular carcinoma (HCC), the most common type of liver cancer, continues to show that the product improves progression-free and overall survival rates.

ThermoDox significantly improves the latter in patients with single lesions if they undergo Radiofrequency Ablation (RFA) for 45 minutes or more. Ablation is the removal of biological tissue. (PR)

Comments (1)
  • hessed
    , contributor
    Comment (1) | Send Message
     
    I always trust in $CLSN
    The stock will fly to $4 soon
    I love you baby come on
    16 Sep 2013, 09:16 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs